Trial Profile

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Gocatamig (Primary)
Indications Bladder cancer; Neuroendocrine carcinoma; Prostate cancer; Small cell lung cancer
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Harpoon Therapeutics

03 Apr 2025 Planned End Date changed from 30 Jun 2027 to 17 Nov 2027.
03 Apr 2025 Planned primary completion date changed from 30 Jun 2027 to 17 Nov 2027.
20 Feb 2025 Planned End Date changed from 27 Feb 2026 to 30 Jun 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com